SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines,South Korea, 2021 |
| |
| Authors: | Seonju Yi Young June Choe Jia Kim Yoo-Yeon Kim Ryu Kyung Kim Eun Jung Jang Do Sang Lim Hye Ryeon Byeon Sangwon Lee Eonjoo Park Seung-Jin Kim Young-Joon Park |
| |
| Affiliation: | Korea Disease Control and Prevention Agency, Cheongju, South Korea (S. Yi, J. Kim, Y.-Y. Kim, R.K. Kim, E.J. Jang, D.S .Lim, H.R. Byeon, S. Lee, E. Park, S.-J. Kim, Y.-J. Park);Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe) |
| |
| Abstract: | We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population). |
| |
| Keywords: | COVID-19 coronavirus SARS-CoV-2 vaccine breakthrough coronavirus disease severe acute respiratory syndrome coronavirus 2 respiratory infections zoonoses viruses South Korea |
|
|
